Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-18 of 18

Sort by

Sort Order Select

Journal Articles

PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Huadong Chen, Xuxu Gou, Ying Mao, Patrick C. O’Leary, Morgan E. Diolaiti, Alan Ashworth

Mol Cancer Ther (2025) 24 (1): 56–68.

https://doi.org/10.1158/1535-7163.MCT-24-0211

Published: 02 January 2025

View articletitled, PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Includes: Supplementary data

Journal Articles

PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors

Anish Thomas, Shaun D. Fontaine, Morgan E. Diolaiti, Parth Desai, Rajesh Kumar, Nobuyuki Takahashi, Linda Sciuto, Samantha Nichols, Alan Ashworth, Felix Y. Feng, Gary W. Ashley, Minh Nguyen, Yves Pommier, Daniel V. Santi

Mol Cancer Ther (2022) 21 (11): 1722–1728.

https://doi.org/10.1158/1535-7163.MCT-22-0217

Published: 03 November 2022

View articletitled, PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors

Includes: Supplementary data

Journal Articles

A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Huadong Chen, Morgan E. Diolaiti, Patrick C. O'Leary, Ajda Rojc, Nevan J. Krogan, Minkyu Kim, Alan Ashworth

Mol Cancer Ther (2022) 21 (7): 1076–1089.

https://doi.org/10.1158/1535-7163.MCT-21-0841

Published: 05 July 2022

View articletitled, A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Includes: Supplementary data

Journal Articles

Modeling Therapy Resistance in BRCA1/2-Mutant Cancers

Amy Dréan, Chris T. Williamson, Rachel Brough, Inger Brandsma, Malini Menon, Asha Konde, Isaac Garcia-Murillas, Helen N. Pemberton, Jessica Frankum, Rumana Rafiq, Nicholas Badham, James Campbell, Aditi Gulati, Nicholas C. Turner, Stephen J. Pettitt, Alan Ashworth, Christopher J. Lord

Mol Cancer Ther (2017) 16 (9): 2022–2034.

https://doi.org/10.1158/1535-7163.MCT-17-0098

Published: 04 September 2017

View articletitled, Modeling Therapy Resistance in BRCA1/2-Mutant Cancers

Includes: Supplementary data

Journal Articles

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Mol Cancer Ther (2016) 15 (7): 1472–1484.

https://doi.org/10.1158/1535-7163.MCT-15-0554

Published: 05 July 2016

View articletitled, Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Includes: Supplementary data

Journal Articles

Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

Mol Cancer Ther (2015) 14 (8): 1824–1836.

https://doi.org/10.1158/1535-7163.MCT-14-0980-T

Published: 05 August 2015

View articletitled, Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

Includes: Supplementary data

Journal Articles

Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways

Marieke Aarts, Ilirjana Bajrami, Maria T. Herrera-Abreu, Richard Elliott, Rachel Brough, Alan Ashworth, Christopher J. Lord, Nicholas C. Turner

Mol Cancer Ther (2015) 14 (4): 865–876.

https://doi.org/10.1158/1535-7163.MCT-14-0845

Published: 09 April 2015

View articletitled, Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways

Includes: Supplementary data

Journal Articles

Abstract A09: Induced aggravation of oxidative DNA damage as a targeted synthetic lethal approach in mismatch repair-deficient tumors

Yari Fontebasso, Christopher J. Lord, Alan Ashworth

Mol Cancer Ther (2013) 12 (5_Supplement): A09.

https://doi.org/10.1158/1535-7163.PMS-A09

Published: 01 May 2014

View articletitled, Abstract A09: Induced aggravation of oxidative DNA damage as a targeted synthetic lethal approach in mismatch repair-deficient tumors

Journal Articles

Abstract B24: Using KRAS synthetic lethality to design novel therapeutic approaches to cancer

Sara Costa-Cabral, Eliana Marinari, Marieke Aarts, Jenna L. Riffell, Christopher Torrence, Christopher L. Lord, Alan Ashworth

Mol Cancer Ther (2013) 12 (5_Supplement): B24.

https://doi.org/10.1158/1535-7163.PMS-B24

Published: 01 May 2014

View articletitled, Abstract B24: Using KRAS synthetic lethality to design novel therapeutic approaches to cancer

Journal Articles

Abstract IA14: Harnessing genetic dependencies in cancer therapy

Alan Ashworth

Mol Cancer Ther (2013) 12 (5_Supplement): IA14.

https://doi.org/10.1158/1535-7163.PMS-IA14

Published: 01 May 2014

View articletitled, Abstract IA14: Harnessing genetic dependencies in cancer therapy

Journal Articles

Abstract A36: A transposon-based genetic screen in haploid mouse embryonic stem cells identifies Parp1 as a major mediator of olaparib toxicity

Stephen J. Pettitt, Farah L. Rehman, Ilirjana Bajrami, Helen Pemberton, Rachel Brough, Iwanka Kozarewa, Christopher J. Lord, Alan Ashworth

Mol Cancer Ther (2013) 12 (5_Supplement): A36.

https://doi.org/10.1158/1535-7163.PMS-A36

Published: 01 May 2014

View articletitled, Abstract A36: A transposon-based genetic screen in haploid mouse embryonic stem cells identifies Parp1 as a major mediator of olaparib toxicity

Journal Articles

Abstract B28: Screening for kinase dependencies in HPV-associated cancer

Tim Fenton, Rachel Brough, Luke Williams, Ilirjana Bajrami, Alan Ashworth, Chris Lord, Chris Boshoff

Mol Cancer Ther (2013) 12 (5_Supplement): B28.

https://doi.org/10.1158/1535-7163.PMS-B28

Published: 01 May 2014

View articletitled, Abstract B28: Screening for kinase dependencies in HPV-associated cancer

Journal Articles

Synthetic Lethal Targeting of PTEN-Deficient Cancer Cells Using Selective Disruption of Polynucleotide Kinase/Phosphatase

Todd R. Mereniuk, Mohamed A.M. El Gendy, Ana M. Mendes-Pereira, Christopher J. Lord, Sunita Ghosh, Edan Foley, Alan Ashworth, Michael Weinfeld

Mol Cancer Ther (2013) 12 (10): 2135–2144.

https://doi.org/10.1158/1535-7163.MCT-12-1093

Published: 07 October 2013

View articletitled, Synthetic Lethal Targeting of PTEN-Deficient Cancer Cells Using Selective Disruption of Polynucleotide Kinase/Phosphatase

Includes: Supplementary data

Journal Articles

Abstract A184: Integrative molecular and functional profiling of HER2 amplified breast cancers to identify new gene targets.

Kai-Keen Shiu, Daniel Wetterskog, Alan Mackay, Rachael Natrajan, Maryou Lambros, David Sims, Ilirjana Bajrami, Rachel Brough, Jessica Frankum, Hugo Horlings, Marc van der Vijver, Nicholas Turner, Jorge Reis-Filho, Christopher Lord, Alan Ashworth

Mol Cancer Ther (2011) 10 (11_Supplement): A184.

https://doi.org/10.1158/1535-7163.TARG-11-A184

Published: 12 November 2011

View articletitled, Abstract A184: Integrative molecular and functional profiling of HER2 amplified breast cancers to identify new gene targets.

Journal Articles

Abstract B201: Identification of miRNA modulators to PARP inhibitor response.

Sari Neijenhuis, Ilirjana Bajrami, James Campbell, Christopher J. Lord, Alan Ashworth

Mol Cancer Ther (2011) 10 (11_Supplement): B201.

https://doi.org/10.1158/1535-7163.TARG-11-B201

Published: 12 November 2011

View articletitled, Abstract B201: Identification of miRNA modulators to PARP inhibitor response.

Journal Articles

Abstract A239: MPS1 (TTK) kinase inhibition selectively kills aneuploid cells

Teeara Rawjee, Martin Rowlands, Craig McAndrew, Mark Stubbs, Christopher J. Lord, Jorge S. Reis‐Filho, Alan Ashworth, Wynne Aherne, Paul Workman, Julian Blagg, Spyridon Linardopoulos

Mol Cancer Ther (2009) 8 (12_Supplement): A239.

https://doi.org/10.1158/1535-7163.TARG-09-A239

Published: 10 December 2009

View articletitled, Abstract A239: MPS1 (TTK) kinase inhibition selectively kills aneuploid cells

Journal Articles

Synthetic Lethal Approaches to the Treatment of Cancers with DNA Repair Defects

Alan Ashworth

Mol Cancer Ther (2007) 6 (11_Supplement): CN08-04.

Published: 01 November 2007

View articletitled, Synthetic Lethal Approaches to the Treatment of Cancers with DNA Repair Defects

Journal Articles

Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment

Benjamin J. Friedmann, Martyn Caplin, Boris Savic, Tahir Shah, Christopher J. Lord, Alan Ashworth, John A. Hartley, Daniel Hochhauser

Mol Cancer Ther (2006) 5 (2): 209–218.

https://doi.org/10.1158/1535-7163.MCT-05-0239

Published: 27 February 2006

View articletitled, Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors

A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Modeling Therapy Resistance in BRCA1/2-Mutant Cancers

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways

Abstract A09: Induced aggravation of oxidative DNA damage as a targeted synthetic lethal approach in mismatch repair-deficient tumors

Abstract B24: Using KRAS synthetic lethality to design novel therapeutic approaches to cancer

Abstract IA14: Harnessing genetic dependencies in cancer therapy

Abstract A36: A transposon-based genetic screen in haploid mouse embryonic stem cells identifies Parp1 as a major mediator of olaparib toxicity

Abstract B28: Screening for kinase dependencies in HPV-associated cancer

Synthetic Lethal Targeting of PTEN-Deficient Cancer Cells Using Selective Disruption of Polynucleotide Kinase/Phosphatase

Abstract A184: Integrative molecular and functional profiling of HER2 amplified breast cancers to identify new gene targets.

Abstract B201: Identification of miRNA modulators to PARP inhibitor response.

Abstract A239: MPS1 (TTK) kinase inhibition selectively kills aneuploid cells

Synthetic Lethal Approaches to the Treatment of Cancers with DNA Repair Defects

Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only